Olezarsen for Chylomicronemia Syndrome

This trial aims to test the effectiveness of olezarsen in children with Familial Chylomicronemia Syndrome (FCS), a rare genetic condition that causes very high blood fat levels. Participants will receive regular injections of olezarsen over one year, with an option to continue for an additional year. Children with a confirmed FCS diagnosis, who can fast before some visits and are free from certain health issues like recent surgery or active pancreatitis, may be suitable for this study. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants the opportunity to contribute to a treatment nearing widespread availability.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that olezarsen is generally safe for people with familial chylomicronemia syndrome (FCS). Earlier studies found olezarsen to be safe and well-tolerated, with most participants experiencing no serious side effects.

Common side effects included injection site reactions, joint pain, and a decrease in platelet count (the cells that help blood clot). These side effects were usually mild to moderate, and no major bleeding was reported. Interestingly, side effects occurred more frequently in the placebo group than in those who received olezarsen.

Olezarsen is unique because it targets the root cause of chylomicronemia syndrome by reducing the production of apoC-III, a protein that plays a key role in lipid metabolism. Unlike current treatments like dietary restrictions and fibrates, which manage symptoms, olezarsen aims to directly address the underlying issue. Researchers are excited about olezarsen because it offers a novel mechanism of action and is administered via a convenient subcutaneous injection, potentially improving patient adherence and outcomes.

Research has shown that olezarsen can significantly lower triglyceride levels in people with familial chylomicronemia syndrome (FCS). In previous studies, olezarsen reduced triglycerides by about 60% over a year and completely prevented episodes of acute pancreatitis, a serious condition where the pancreas becomes inflamed. These findings suggest that olezarsen effectively manages important symptoms of FCS. Overall, the treatment has consistently produced positive results in lowering triglyceride levels and preventing related complications in FCS patients. Participants in this trial will receive olezarsen in different cohorts based on age, with dosing adjusted accordingly.²³⁶⁷⁸